Literature DB >> 3874329

The antitumour effect of doxycycline on a T-cell leukaemia in the rat.

C van den Bogert, B H Dontje, A M Kroon.   

Abstract

Previous studies showed that T-lymphoid cells are permeable to the tetracyclines, whereas B-lymphoid and erythroid cells are not. The tetracyclines impair mitochondrial protein synthesis if they have access to cells. Inhibition of mitochondrial protein synthesis during a number of cell cycles results, as a consequence, in proliferation arrest. The tetracyclines can therefore be considered as cytostatics. In the present study the effect of prolonged treatment with doxycycline on the growth of a T-cell type leukaemia of the rat was investigated. It is shown that doxycycline treatment inhibits not only tumour cell proliferation, but leads moreover to complete tumour eradication. The way by which the latter is achieved depends on the doxycycline concentration and, surprisingly, on the stage of tumour progression at which doxycycline administration is started. As, because of the permeability barrier, the proliferation of erythroid and B-lymphoid cells is not affected by the tetracyclines, the tetracyclines may provide a tool without serious side-effects in the therapy of T-type tumours.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874329     DOI: 10.1016/0145-2126(85)90142-0

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

1.  Ultrastructure and dynamics of selective mitochondrial injury in carcinoma cells after doxycycline photosensitization in vitro.

Authors:  C R Shea; D Whitaker; G F Murphy; T Hasan
Journal:  Am J Pathol       Date:  1988-11       Impact factor: 4.307

Review 2.  Mitochondrial ribosomes in cancer.

Authors:  Hyun-Jung Kim; Priyanka Maiti; Antoni Barrientos
Journal:  Semin Cancer Biol       Date:  2017-04-23       Impact factor: 15.707

3.  Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells.

Authors:  Q Meng; J Xu; I D Goldberg; E M Rosen; R A Greenwald; S Fan
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  A cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer model.

Authors:  Matthew T Basel; Sivasai Balivada; Tej B Shrestha; Gwi-Moon Seo; Marla M Pyle; Masaaki Tamura; Stefan H Bossmann; Deryl L Troyer
Journal:  Small       Date:  2012-01-11       Impact factor: 13.281

Review 5.  Clonal expansion of T cells in abdominal aortic aneurysm: a role for doxycycline as drug of choice?

Authors:  Albert M Kroon; Jan-Willem Taanman
Journal:  Int J Mol Sci       Date:  2015-05-18       Impact factor: 5.923

6.  Tetracycline derivative minocycline inhibits autophagy and inflammation in concanavalin-a-activated human hepatoma cells.

Authors:  Michel Desjarlais; Jonathan Pratt; Amine Lounis; Catherine Mounier; Khadidja Haidara; Borhane Annabi
Journal:  Gene Regul Syst Bio       Date:  2014-03-04

7.  Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cells.

Authors:  Hairong Song; Mona Fares; Kim R Maguire; Ake Sidén; Zuzana Potácová
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

8.  Minocycline treatment suppresses juvenile development and growth by attenuating insulin/TOR signaling in Drosophila animal model.

Authors:  Hyun Myoung Yun; Sujin Noh; Seogang Hyun
Journal:  Sci Rep       Date:  2017-03-20       Impact factor: 4.379

9.  Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.

Authors:  Parvin Ataie-Kachoie; David L Morris; Mohammad H Pourgholami
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

10.  Minocycline treatment increases resistance to oxidative stress and extends lifespan in Drosophila via FOXO.

Authors:  Gang Jun Lee; Jin Ju Lim; Seogang Hyun
Journal:  Oncotarget       Date:  2017-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.